Skip to main content

Table 3 Associations between APC methylation and clinicopathological features in tumor DNA. Analysis of 216 MSI-H and 216 MSS CRC patients from Ontario and Newfoundland

From: Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients

  MSS (n = 216) MSI-H (n = 216)
  Unmethylated (%) Methylated (%) OR (95 % CI)a P-value Unmethylated (%) Methylated (%) OR (95 % CI)a P-value
Age         
 <50 20 (13.8) 10 (14.1) 0.976 (0.431–2.213) 0.954 23 (17.6) 15 (17.9) 0.994 (0.485–2.035) 0.986
 50+ 125 (86.2) 61 (85.9)    108 (82.4) 70 (82.4)   
Sex         
 Male 64 (44.1) 35 (49.3) 0.813 (0.460–1.436) 0.475 59 (45.0) 41 (48.2) 0.879 (0.509–1.520) 0.645
 Female 81 (55.9) 36 (50.7)    72 (55.0) 44 (51.8)   
TNM Stageb         
 1 27 (18.6) 23 (32.4) 0.391 (0.095–1.619) 0.147 32 (24.4) 17 (20.0) 0.653 (0.533–0.801) 0.306
 2 79 (54.5) 31 (43.7)    64 (48.9) 48 (56.5)   
 3 30 (20.7) 14 (19.7)    31 (23.7) 20 (23.5)   
 4 9 (6.2) 3 (4.2)    4 (3.1) 0 (0.0)   
Histological Gradeb         
 Low 12 (8.9) 8 (12.1) 0.600 (0.163–2.207) 0.724 8 (11.0) 9 (17.0) 0.770 (0.230–2.578) 0.467
 Moderate 108 (80.0) 52 (78.8)    50 (68.5) 31 (58.5)   
 High 15 (11.1) 6 (9.1)    15 (20.5) 13 (24.5)   
Locationc         
 Proximal 62 (44.0) 25 (36.2) 1.381 (0.763–2.499) 0.285 63 (85.1) 51 (92.7) 0.449 (0.135–1.495) 0.183
 Distal 79 (56.0) 44 (63.8)    11 (14.9) 4 (7.3)   
Histological Typed         
 Non-Mucinous 129 (89.6) 60 (87.0) 1.290 (0.534–3.114) 0.570 87 (68.5) 62 (73.8) 0.772 (0.418–1.426) 0.408
 Mucinous 15 (10.4) 9 (13.0)    40 (31.5) 22 (26.2)   
MMR Protein Status         
 Intact 132 (97.8) 66 (98.5) 0.668 (0.068–6.533) 0.726 21 (16.3) 9 (10.8) 1.599 (0.694–3.685) 0.268
 Deficient 3 (2.2) 1 (1.5)    108 (83.7) 74 (89.2)   
MMR Germline Mutation         
 No 144 (99.3) 71 (100.0) 0.670 (0.610–0.736) 0.483 104 (79.4) 59 (69.4) 1.697 (0.908–3.175) 0.096
 Yes 1 (0.7) 0 (0.0)    27 (20.6) 26 (30.6)   
MLH1 Methylation         
 Unmethylated 131 (96.3) 64 (98.5) 0.409 (0.047–3.577) 0.405 62 (47.3) 48 (56.5) 0.693 (0.400–1.199) 0.189
 Methylated 5 (3.7) 1 (1.5)    69 (52.7) 37 (43.5)   
BRAF V600E Mutation         
 No 126 (90.6) 66 (94.3) 0.587 (0.184–1.873) 0.364 67 (53.2) 53 (66.3) 0.579 (0.324–1.034) 0.064
 Yes 13 (9.4) 4 (5.7)    59 (46.8) 27 (33.8)   
CIMP Status         
 Negative 91 (92.9) 42 (93.3) 0.929 (0.229–3.770) 0.917 45 (52.3) 34 (60.7) 0.710 (0.359–1.406) 0.325
 Positive 7 (7.1) 3 (6.7)    41 (47.7) 22 (39.3)   
Survival Status         
 Alive 95 (65.5) 50 (70.4) 0.782 (0.424–1.444) 0.432 91 (69.5) 57 (67.1) 1.118 (0.622–2.007) 0.710
 Deceased 50 (34.5) 21 (29.6)    40 (30.5) 28 (32.9)   
  1. aOdds ratio and 95 % confidence interval for methylated versus unmethylated
  2. bOR and 95 % CI given for lowest stage/grade versus highest stage/grade
  3. cProximal tumor location includes lesions up to and including the splenic flexure
  4. dMucinous histology includes the presence of any mucin within the tumor stroma